Presentations
Publications

Scientific Presentations

date

document

Scientific Publications

  • Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

    Authors: Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, Bernard Escudier, Thomas E. Hutson, Vijay Kasturi, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Elena Verzoni. Click here for link to article.

  • Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

    Authors: Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal. Click here for link to article.

  • Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer, an NCCN phase II Trial

    Authors: Mathew Cowan, Wendy M. Swetzig, Valery Adorno-Cruz, Mario J. Pineda, Nikki L. Neubauer, Emily Berry, John R. Lurain, Shohreh Shahabi, Deanna Taiym, Valerie Nelson, Kaitlyn Lucrezia O’Shea, Masha Kocherginsky, Daniela Matei. Click here for link to article.

  • Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

    Authors: Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C. Logan, Matthew Settles, Gabriel N. Mannis, Rebecca Olin, Lloyd E. Damon, Thomas G. Martin, Peter H. Sayre, Karin M. Gaensler, Emma McMahon, Michael Flanders, Vivian Weinberg, Chun J. Ye, David P. Carbone, Pamela N. Munster, Gabriela K. Fragiadakis, Frank McCormick, Charalambos Andreadis. Click here for link to article.

  • TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

    Authors: L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, M. N. Needle, B. Escudier. Click here for link to article.

  • Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

    Authors: Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini. Click here for link to article.

  • A Multicentre Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

    Authors: Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile. Click here for link to article.

  • A Multicentre Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma

    Authors: Christos Fountzilas, Medhavi Gupta, Sunyoung Lee, Smitha Krishnamurthi, Bassam Estfan, Katy Wang, Kristopher Attwood, John Wilton, Robert Bies, Wiam Bshara, Renuka Iyer. Click here for link to article.

  • Real-World Results from One Year of Therapy with Tivozanib

    Authors: Michael Staehler, Annabel K. Spek, Severin Rodler, Melanie Schott, Jozefina Casuscelli, Lena Mittelmeier, Marcus Schlemmer. Click here for link to article.

  • BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

    Authors: Al B. Benson III, Igor Kiss, John Bridgewater, Ferry A.L.M. Eskens, Carolyn Sasse, Sandra Vossen, Jihong Chen, Chip Van Sant, Howard A. Ball, Anne Keating, Andrew Krivoshik. Click here for link to article.

  • Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study

    Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott. Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.

  • Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

    Authors: Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E. Hutson. Click here for link to article.

  • Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

    Authors: Ana M. Molina, Thomas E. Hutson, Dmitry Nosov, Piotr Tomczak, Oleg Lipatov, Cora N. Sternberg, Robert Motzer, Tim Eisen. Click here for link to article.

  • Tan – Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Gth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

    Authors: Eng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, Quan-Sing Ng, Jin Seok Ahn, Daniel Shao-Weng Tan, Jong-Mu Sun, May Han, Francis C. Payumo, Krista McKee, Wei Yin, Marc Credi, Shefali Agarwal, Jaroslaw Jac, Keunchil Park. Click here for link to article.

  • Mok – Ph2 Combo Fic and Gefitinib in Asian Pts with Pulmonary Adenocarcinoma

    Authors: Tony Shu Kam Mok, Sarayut Lucien Geater, Wu-Chou Su, Eng-Huat Tan, James Chi-Hsin Yang, Gee-Chen Chang, May Han, Philip Komarnitsky, Francis Payumo, Jennifer E. Garrus, Sandra Close, Keunchil Park. Click here for link to article.

  • Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic onization

    Authors: Shigetsugu Takano, Maximilian Reichert, Basil Bakir, Koushik K. Das, Takahiro Nishida, Masaru Miyazaki, Steffen Heeg, Meredith A. Collins, Benoît Marchand, Philip D. Hicks, Anirban Maitra, Anil K. Rustgi. Click here for link to article. Click here for link to Supplemental Text and Figures.

  • Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

    Authors: Dmitry A. Nosov, Brooke Esteves, Oleg N. Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju T. Chacko, Dinesh C. Doval, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava. Click here for link to article.

  • Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.

    Authors: Ferry A. L. M. Eskens, Maja J. A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij. Click here for link to article.

  • Development of second-generation VEGFR tyrosine kinase inhibitors: Current status

    Authors: Pankaj Bhargava, Murray O. Robinson. Click here for link to article.

  • GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

    Authors: Ailin Bai, Kristan Meetze, Nhi Y. Vo, Sriram Kollipara, Elizabeth K. Mazsa, William M. Winston, Solly Weiler, Laura L. Poling, Ting Chen, Nesreen S. Ismail, Jinwei Jiang, Lorena Lerner, Jeno Gyuris, Zhigang Weng. Click here for link to article.

  • Non-germline genetically engineered mouse models for translational cancer research

    Authors: Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe, Lynda Chin. Click here for link to article.

  • Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

    Authors: Yinghui Zhou, William M. Rideout III, Tong Zi, Angela Bressel, Shailaja Reddypalli, Rebecca Rancourt, Jin-Kyeung Woo, James W. Horner, Lynda Chin, M. Isabel Chiu, Marcus Bosenberg, Tyler Jacks, Steven C. Clark, Ronald A. DePinho, Murray O. Robinson, Joerg Heyer. Click here for link to article.

  • Essential role for oncogenic Ras in tumour maintenance

    Authors: Lynda Chin, Alice Tam, Jason Pomerantz, Michelle Wong, Jocelyn Holash, Nabeel Bardeesy, Qiong Shen, Ronan O’Hagan, Joe Pantginis, Hao Zhou, James W. Horner II, Carlos Cordon-Cardo, George D. Yancopoulos, Ronald A. DePinho. Click here for link to article.

The listed publications and presentations discuss investigational new drugs that have not been approved by the U.S. Food and Drug Administration.